Analyst Ratings For Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Today, Ladenburg Thalmann Financial Services initiated coverage on Zynerba Pharmaceuticals (NASDAQ:ZYNE) with a Buy with a price target of $25.50.
Some recent analyst ratings include
- 1/29/2018-Ladenburg Thalmann Financial Services initiated coverage with a Buy rating.
- 1/26/2018-Seaport Global Securities initiated coverage with a Buy rating.
- 1/3/2018-Oppenheimer Reiterated Rating of Hold.
Recent Insider Trading Activity For Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Zynerba Pharmaceuticals (NASDAQ:ZYNE) has insider ownership of 9.91% and institutional ownership of 26.42%.
- On 1/2/2018 Michael Rapp, Major Shareholder, bought 15,000 with an average share price of $12.99 per share and the total transaction amounting to $194,850.00.
- On 10/23/2017 Michael Rapp, Major Shareholder, bought 25,745 with an average share price of $9.94 per share and the total transaction amounting to $255,905.30.
- On 10/19/2017 Michael Rapp, Major Shareholder, bought 44,255 with an average share price of $9.59 per share and the total transaction amounting to $424,405.45.
- On 5/15/2017 Armando Anido, Chairman, bought 5,000 with an average share price of $19.70 per share and the total transaction amounting to $98,500.00.
- On 5/12/2017 James E Fickenscher, CFO, bought 5,200 with an average share price of $19.82 per share and the total transaction amounting to $103,064.00.
- On 12/29/2016 Michael Rapp, Major Shareholder, bought 10,000 with an average share price of $15.85 per share and the total transaction amounting to $158,500.00.
- On 12/7/2016 James E Fickenscher, CFO, bought 7,000 with an average share price of $14.08 per share and the total transaction amounting to $98,560.00.
Recent Trading Activity for Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Shares of Zynerba Pharmaceuticals closed the previous trading session at 12.56 up +0.49 4.06% with 309013 shares trading hands.